Top Markets
Coin of the day
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Pozycja w akcjach #5731
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Cena akcji
$29.86
Ostatnia synchronizacja: 2026-08-19
Kapitalizacja rynkowa
$2.48B
Zmiana (1 dzień)
4.92%
Zmiana (1 rok)
502.82%
Kraj
TW
Handel Lin BioScience, Inc. (6696)

Kategoria

Historia stopy dywidendy dla Lin BioScience, Inc. (6696)
Stopa dywidendy (TTM) dla Lin BioScience, Inc. (symbol akcji: 6696) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Lin BioScience, Inc. (6696) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji